A1 Oncology

Topic

Cancer arises when a cell loses the mechanisms that normally keep its proliferation in check. Under normal conditions, there is a balance between signals that stimulate and those that inhibit cell division; when this balance shifts toward growth, the cell acquires the capacity for unlimited replication, and its descendants progressively form a mass of cells: the tumor.

This transformation does not happen all at once. With each division, there is a small probability of mutations appearing; these accumulate progressively and in a largely random manner. Most have little functional significance, but some affect genes that are fundamental to controlling proliferation. The accumulation of approximately five to ten of these key alterations can complete the malignant transformation, producing a cell population capable of proliferating without normal controls.

Tumor growth changes over the course of its evolution. Initially, when the tumor is small and has sufficient space and nutrients, it may grow roughly exponentially: as the number of cells increases, so does the absolute growth rate. Subsequently, constraints related to nutrients, space, and the immune response emerge, and growth begins to slow down, progressively approaching a limit. There is an intermediate stage—at roughly one-third of the tumor's eventual maximum size—where the growth rate peaks; the rate increases before this point and decreases afterward, even though the mass itself continues to grow.

When the tumor exceeds a certain size, cells in the central regions become distant from blood vessels and receive less oxygen, resulting in intratumoral hypoxia. This lack of oxygen triggers molecular mechanisms that simultaneously promote the formation of new blood vessels, changes in energy metabolism, and increased resistance to programmed cell death. The resulting angiogenesis provides the tumor with its own blood supply, allowing it to partially overcome nutrient limitations and continue growing.

Hypoxia also has implications for treatment. Tumor cells with low oxygen availability may be more resistant to radiotherapy, as the presence of oxygen enhances the effectiveness of radiation-induced damage. Thus, the very conditions that favor tumor adaptation and progression can also hinder treatment.

During growth, some malignant cells may break away from the original tumor, enter blood or lymphatic vessels, and reach other organs, initiating metastasis. Dissemination is linked to the tumor's outer surface, where there is contact with the pathways allowing cells to escape. Since surface area increases more slowly than volume as a mass grows, doubling the tumor's size does not mean a proportional doubling of its dissemination potential. However, in absolute terms, a large tumor has a greater surface area and therefore presents more overall opportunities to generate metastases than a small one.

Growth rates vary enormously among different cancers. Some highly aggressive tumors, such as Burkitt lymphoma, can double in size in a few days; many breast cancers may do so over one or several months, whereas numerous prostate cancers may take close to a year or more. These differences are clinically important because they determine the time available to detect a tumor before it progresses significantly.

Proliferation rate also influences treatment. Some chemotherapy agents act primarily on dividing cells; consequently, their efficacy depends partly on the proportion of tumor cells that are actively proliferating. Rapidly growing tumors may contain a larger fraction of cells susceptible to these treatments, whereas slow-growing tumors exhibit different dynamics.

Overall, cancer progression depends on the accumulation of mutations that disrupt proliferation control, the growth dynamics of the tumor population, space and nutrient constraints, adaptation to hypoxia through angiogenesis and metabolic changes, and the cells' ability to disseminate and form metastases. The speed at which these processes occur determines the window for detection, the progression of the disease, and the response to specific treatments.

ID:2262